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OriginalClinicalScienceçGeneralExposure to Mycophenolate and Fatherhood
Karsten Midtvedt, MD, PhD,1 Stein Bergan, PhD,2,3 Anna Varberg Reisæter, MD, PhD,1,4
Bjørn Egil Vikse, MD, PhD,5,6 and Anders Åsberg, PhD1,3,4Background.Mycophenolic acid (MPA) is the active immunosuppressive substance in both mycophenolate mofetil and myco-
phenolate sodium, and it is widely used after organ transplantation. In women, taking MPA is teratogenic and may also influence
spermatogenesis. There is a lack of knowledge regarding outcome of pregnancies fathered bymen exposed toMPA.Methods.
We compared outcomes in pregnancies fathered by renal transplant men per whether they had been exposed to MPA or not at
time of conception. A nationwide population-based retrospective cohort study was performed. Data from the Norwegian Renal
Registry with all renal transplanted men alive between January 1, 1995 and December 31, 2015 were included, and relevant out-
come data were extracted from the Medical Birth Registry of Norway. Results. During the given time, 230 immunosuppressed
renal transplanted men fathered 350 children (155 on MPA/195 not on MPA). There were no significant increased risks of malfor-
mation (3.9% vs. 2.6%, P = 0.49) in MPA exposed versus unexposed cohorts of children. The average dose (±SD) of mycophe-
nolate was 1.42 ± 0.3 g/day and the individual median MPA trough concentration in the time period of anticipated conception and
pregnancy was 2.8 ± 1.6 mg/L. Birth weight was similar in exposed and unexposed cohorts of children; 3381 ± 681 g vs.
3429 ± 714 g (P = 0.53).Conclusions.Paternal exposure toMPA did not increase the risk of adverse birth outcomes in children
fathered by male kidney transplanted patients. These results are reassuring and support the continuation of paternal MPA treat-
ment before, during, and after conception.
(Transplantation 2017;101: e214–e217)End-stage renal disease patients commonly experiencesexual disturbance and reduced fertility. Successful re-
nal transplantation can restore these functions in both male
and female patients.1,2Women are, in general, recommended
to refrain from taking any medication during pregnancy.
Transplant recipients, regardless of sex, must however take
lifelong immunosuppressive medication to preserve their trans-
plant function. It has therefore been a focus on pregnancy safety
and outcome for immunosuppressed women.3-5 Mycophe-
nolic acid (MPA) is the active immunosuppressive substance
in both mycophenolate mofetil (MMF) and mycophenolate
sodium (MPS), and it reduces the incidence of acute rejection
and benefits graft survival.6 From previous studies, it is well
known that exposure to MPA in early pregnancy of femaleReceived 16 January 2017. Revision received 3 March 2017.
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e214 www.transplantjournal.comtransplant recipients has been associated with increased rate
of miscarriages and birth defects in the live born.7,8 Accord-
ingly, common practice in female patientswhowish to become
pregnant is either to withdrawMPA or switch to azathioprine
before conception. Recently, the manufacturers of MMF
(CellCept; Roche, Basel) andMPS (Myfortic; Novartis, Basel)
and the European Medicines Agency (EMA) recommended
additional measurements to prevent MPA exposure in preg-
nancy.9 The warning states: “sexually active men taking
mycophenolate are recommended to use condom for sex
during treatment and for 90 days thereafter; partners of
childbearing potential are also recommended to use highly
effective contraception for the same period.”9 There is very
limited published data on the effect of MPA on human
sperm and the possible effects of children whose fatherscollected the MPA exposure trough values and approved of the final manuscript.
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could only find one publication and the results published
did not support the EMA recommendations.10 There is
an increased risk of acute rejection and graft loss associ-
ated with withdrawal of MPA. The transplant community
was therefore puzzled by the EMAwarning.11,12 Was this
EMA recommendation solely due to precautionary mea-
sures? Obviously, there was and is a need for more data.
We therefore decided to perform a population-based na-
tionwide retrospective study comparing outcomes in preg-
nancies fathered by renal transplant men either exposed to
MPA or not at time of conception and/or pregnancy.
MATERIALS AND METHODS
A national population-based study was designedwith focus
on the time period from 1995 to 2015. Transplanted men
alive between January 1, 1995 and December 31, 2015 were
identified in the Norwegian Renal Registry (NRR). Data
from the Medical Birth Registry of Norway (MBRN) was
collected for the same time period. The registry was estab-
lished in 1967 and was the first national medical birth regis-
try in the world. It is based on compulsory notification of all
live births and stillbirths from gestational week 16 initially
(1967–2001) and since 2002 from week 12. To ensure med-
ical notification of every newborn in Norway, all records in
the MBRN are matched with files of the Central Person Reg-
istry.13 Linkage between the data from the NRR andMBRN
were merged utilizing the unique 11-digit personal identifica-
tion number given to every Norwegian citizen at birth.
Data onMPA exposure was extracted fromNRR. Patients
with registered use ofMPA drugs the year of birth or the year
before were defined as “MPA-exposed.” Trough concentra-
tions of MPA for the same time period were searched for
and obtained (when measured) from the hospital laboratory
system for all patients in the MPA-exposed group. If no
trough MPA concentration was measured, all patient charts
were manually cross-checked for accuracy in reported MPA
usage to NRR in all patients defined as MPA-exposed above.
Data extracted from theMBRN included demographics on
mother and father, previous births and spontaneous abortions
of the mother, health status of the mother before and during
pregnancy, and pregnancy and birth outcomes including birth
complications, pregnancy duration, birth weight, stillbirths,
perinatal death, APGAR score, and malformations.
Immunosuppressive protocols used by the patients included
in the study have varied depending primarily on time period
of engraftment. All recipients have received steroids and a
calcineurin inhibitor at time of engraftment. From 1995 to
2008, more or less all recipients received cyclosporine A.
From January 1, 2009, recipients <50 years received tacroli-
mus, and from January 1, 2012, all recipients have received
tacrolimus. Azathioprine was used from 1995 to December
31, 2000. After that, all recipients have receivedMPA. Induc-
tion with basiliximab was started in 2000. Some patients
have been included in clinical trials with either switch to
mTOR (everolimus/sirolimus), use of JAK 3-inhibitor, or
belatacept. Data from these patients were not included in
the final evaluation.
Statistical Analyses
Differences between the MPA exposed and MPA not ex-
posed groups were statistically compared with logistic andlinear regression methods adjusting for repeated fatherhood
both within and between groups by clustered sandwich esti-
mator for adjusting the standard errors. R was used for data
management and statistical analyses.14,15
RESULTS
A total of 6032 renal transplant recipients were alive during
this time, 3974 men/2058 women, and a total of 4000 had
been exposed toMPA (2681M/1319 F). During the time pe-
riod, a total of 230 immunosuppressed renal transplanted
males fathered 350 children. Moreover, 136 men fathered 1
child, 73 men fathered 2 children, and 21 fathered 3 or more
children. At the estimated time of conception, there were 112
different male transplant recipients who fathered 155 chil-
dren under MPA exposure and 133 male recipients who fa-
thered 195 children without MPA exposure. Fifteen men
fathered children both as exposed and unexposed to MPA.
In the early phase of MPA use, trough measurements on sta-
ble maintenance patients were not always performed. We
were, however, able to trace validMPA trough concentration
measurements for the actual time period for 117 of the 155
MPA exposed patients. The average dose (±SD) of mycophe-
nolate was 1.42 ± 0.3 g/day and individual median MPA
trough concentration in the time period of anticipated con-
ception and pregnancy was 2.8 ± 1.6 mg/L. For the remain-
ing 38 patients, we found verification in hospital journals
of MPA use at time of conception. There were no clinical dif-
ferences between the age of the fathers onMPAversus not on
MPA (36.1 ± 5.6 vs. 35.7 ± 6.0 years, P = 0.59) or age of
mothers to these children (31.9 ± 4.7 vs. 31.0 ± 4.8 years,
P = 0.12). Mean gestational age was also not different be-
tween the groups, 38.8 ± 2.5 and 39.1 ± 2.7 weeks, respec-
tively (P = 0.30). When comparing other available data
from the MBRN, we could not detect any overall differences
between outcomes in the two groups (Table 1).
There was no difference in malformations in children fa-
thered byMPA exposed versus nonexposed recipients. There
were no significant differences with regards to mother’s
health before or during respective pregnancy or medication
used during pregnancy (data not shown). Preeclampsia oc-
curred in 7 (4.5%) and 14 (7.3%) births fathered by exposed
and nonexposed to MPA, respectively.
DISCUSSION
The results indicate no difference in congenital malforma-
tion or other unwanted outcomes when comparing pregnan-
cies whether the father was exposed to or not exposed to
MPA. This supports the previous findings published by Jones
et al and questions the validity of the EMA recommendations.
After a successful organ transplantation, recipients are faced
with the need of lifelong immunosuppressive medication to
preserve their transplant function. Kidney transplantation
by far outnumbers other organs. Because approximately
40% to 50% of men receiving a kidney transplant are youn-
ger than 50 years of age, the fertility and possibility of father-
hood of male renal transplant recipients is a concern. There
have, however, been very few reports that have investigated
the potential effect of immunosuppressants on the male fertility
and on the offspring.10,16 Currently, the most common
worldwide posttransplant immunosuppressive combination
consists of glucocorticoids, tacrolimus, andMPA. Additional
TABLE 1.
Birth outcomes between exposed (MPA+) and not exposed
(MPA−) groups
MPA+ MPA−
P valueN = 155 N = 195
Acute caesarean section 16 (10.3%) 24 (12.3%) 0.39
Normal placenta 121 (78.1%) 118 (60.5%) 0.32
Child weight (g) 3381 ± 681 3429 ± 714 0.53
Gestational age (wk) 38.9 ± 2.5 39.1 ± 2.7 0.30
Child length (cm) 49.6 ± 3.2 49.9 ± 3.0 0.32
Child head circumference (cm) 34.7 ± 2.1 35.1 ± 2.1 0.12
APGAR score after 1 min 8.6 ± 1.5 8.6 ± 1.5 0.97
APGAR score after 5 min 9.3 ± 1.3 9.3 ± 1.4 0.41
Stillborn 1 (0.6%) 4 (2.1%) 0.12
Born alive, dead within 24 h 0 (0.0%) 1 (0.5%) 0.32
Congenital malformations 6 (3.9%) 5 (2.6%) 0.49
Respiratory distress syndrome 4 (2.6%) 2 (1.0%) 0.40
Neural tube defects 0 (0.0%) 0 (0.0%) 1.00
Icterus 11 (7.1%) 12 (6.2%) 0.33
Hip dysplasia 1 (0.6%) 1 (0.5%) 1.00
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may affect the spermatogenesis. This makes it impossible to
pinpoint one specific drug used by the father at time of con-
ception as “the sinner” causing possible adverse birth out-
comes. There have been some animal studies and some very
few human studies addressing a possible difference in the cal-
cineurin inhibitors cyclosporine A and tacrolimus on the sper-
matozoa.2,16,17 Results are conflicting. Recently, Nørgård et al
published a large study focusing on birth outcome in children
fathered by men treated with azathioprine due to inflamma-
tory bowel disease,18 ie, not using other immunosuppressive
drugs. They found no increased risk of adverse birth out-
comes. There is no such study addressing monotherapy with
MPA. For ethical reasons, randomized trials cannot be de-
signed to evaluate the safety of drugs like MPA during con-
ception. Therefore, we have to base clinical decisions on
evidence from observational registry studies.
In this evaluation, we have not compared outcome of chil-
dren conceived from immunosuppressed fatherswith the out-
come of the general population. This comparison was, however,
recently performed by Morken et al,19 but from a different
time interval and also including data from other organ trans-
plant recipients. In their analysis, they compared data from
4614 pregnancies before and 474 after transplantation to
the outcome in the general population and found an in-
creased risk of preeclampsia. The risk of preeclampsia was
increased (OR: 7.4, 95%CI: 1.1–51.4) after transplantation.
They write that a “causal link between a specific immuno-
suppressive drug and preeclampsia is thus difficult to estab-
lish.” Importantly, no increased risk was found for
congenital malformations or other outcomes when com-
pared with pregnancies before transplantation or with the
general population (2,511,506 births), ie, findings not
supporting the EMA recommendations. Number of fathers
exposed to MPAwas not specified.
A strength of the current study is its design being a nation-
wide population-based cohort study. Oslo University Hospitalis the only transplant center in Norway serving approxi-
mately 5 million inhabitants and has kept complete lifelong
records of all transplanted individuals since 1969, including
immunosuppressive drugs used. We do not have direct data
on drug adherence but becauseMPA trough only is analyzed
at the Oslo University Hospital laboratory, we could verify a
valid trough value around timeof conception for themajority of
the male recipients. Additionally, we could evaluate mother’s
health before or during respective pregnancy—finding no
difference. A drawback is obviously the retrospective design
of the study. It is well known that most miscarriages occur
during the first trimester, and a caveat of our retrospective
registration is that there may have been more miscarriages
during the first trimester if the father was on immunosup-
pression.We are, however, not aware of any national registry
capturing miscarriages this early.
In conclusion, the results indicate no difference in obstetrical
and/or neonatal complicationswhen the father is a transplanted
man on MPA as compared to a transplanted man not on
MPA. Obviously, even more data is needed but in the mean-
time we once again urge the EMA to reconsider their current
recommendations regarding MPA.ACKNOWLEDGMENTS
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